Kiniksa Pharmaceuticals International, plc
KNSA
Peringkat dalam Saham
#2891
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Harga Saham
$82.27
Kapitalisasi Pasar
$6.42B
Perubahan (1 hari)
3.50%
Perubahan (1 tahun)
110.99%
Negara
GB
Perdagangan Kiniksa Pharmaceuticals International, plc (KNSA)
Kategori
Healthcare
Rasio P/S untuk Kiniksa Pharmaceuticals International, plc (KNSA)
Rasio P/S per October 2026 TTM: 7.32
Menurut laporan keuangan dan harga saham terbaru dari Kiniksa Pharmaceuticals International, plc, rasio P/S saat ini (TTM) adalah 7.32. Pada akhir 2023, rasio P/S perusahaan adalah 4.55.
Riwayat rasio P/S untuk Kiniksa Pharmaceuticals International, plc dari 2016 hingga 2026
Rasio P/S pada akhir setiap tahun
| Tahun | Rasio P/S | Mengubah |
|---|---|---|
| 2026 (TTM) | 7.32 | 119.03% |
| 2024 | 3.34 | -26.59% |
| 2023 | 4.55 | -3.68% |
| 2022 | 4.72 | -77.46% |
| 2021 | 20.94 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
Rasio P/S untuk perusahaan sejenis atau pesaing
| Perusahaan | Rasio P/S | Perbedaan Rasio P/S | Negara |
|---|---|---|---|
| 10.31 | 40.94% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 15.12 | 106.72% |
US
|
